DOD Peer Reviewed Cancer, Idea Award | HT942525PRCRPIA

FAQs: FY25 DoD Peer Reviewed Cancer Research Program (PRCRP) Idea Award

1) What is the FY25 PRCRP Idea Award?

The FY25 Department of Defense Peer Reviewed Cancer Research Program (PRCRP) Idea Award is a discretionary research grant intended to launch genuinely new directions in cancer research. It is built for bold, early-stage concepts that have not yet been proven, especially high-risk ideas that could lead to high-reward breakthroughs if successful.

2) What types of projects is this award trying to encourage?

This award is meant to support creative, innovative theories, paradigms, and basic cancer research approaches. The goal is to enable novel pivots and fresh ways of tackling important cancer problems, rather than refining what is already known to work.

3) Is this funding meant for incremental or continuation research?

No. The defining feature of the Idea Award is that it is not intended to fund incremental science. Projects that look like the next predictable step in an existing line of work, small extensions of prior findings, or straightforward repackaging of an established approach are described as poor fits for this mechanism.

4) Would moving an established model or approach to a different cancer type be competitive?

Based on the opportunity description, simply transferring an existing model system from one cancer type to another (without a truly innovative conceptual leap) is explicitly called out as a poor fit. The program is looking for clear innovation rather than a direct translation of an established approach.

5) How does the program define “innovation” for this award?

Innovation here is framed as creative thinking and clear novelty. A strong application should read like a new pivot or fundamentally fresh approach to an important cancer problem, not a refinement, optimization, or predictable extension of work already underway.

6) Are preliminary data required?

No. Preliminary data are not required for this award.

7) If preliminary data are not required, what does the application need to include to be credible?

Even without preliminary data, the proposal must stand on a strong scientific rationale. Applicants need to make a convincing case that the underlying logic is sound, the question being asked matters, and the approach is credible even if it is exploratory and untested.

8) What is the broader mission or intended impact of this award?

The program’s purpose is tied to improving cancer knowledge, patient care, and treatment options that matter within the Military Health System. The mission focus is framed around impact for active-duty Service Members, Veterans, and other military beneficiaries, and by extension, the general public.

9) Who is offering or administering this funding opportunity?

The opportunity is offered by the Department of the Army through USAMRAA (U.S. Army Medical Research Acquisition Activity).

10) What type of funding instrument is used?

The funding instrument is a grant.

11) What is the activity category for this opportunity?

The activity category is listed as science and technology and other research and development.

12) Who is eligible to apply?

Eligibility is listed as unrestricted. In practice, this typically means a wide range of applicant organizations may apply, subject to standard federal grant rules and any additional requirements described in the full announcement.

13) What is the opportunity number?

The opportunity number is HT942525PRCRPIA.

14) What CFDA number is associated with this opportunity?

This opportunity is associated with CFDA 12.420.

15) What is the application deadline?

The listing indicates an original closing date of September 25, 2025.

16) How many awards are anticipated?

The opportunity indicates an anticipated 25 awards.

17) Is an award ceiling amount provided in the information shown?

No. The provided text does not include an award ceiling amount.

18) What is the FY25 budgeting change mentioned, and why does it matter?

A key FY25 change is that funding limits are now expressed as total costs. When the cap is specified in the full solicitation, it will include both direct and indirect costs combined. This matters because institutions with negotiated indirect cost rates must ensure the full proposed budget (not only direct research expenses) stays within the program limit.

19) Does the description say whether the budget cap includes indirect costs?

Yes. The description notes that, for FY25, limits are expressed as total costs, meaning direct plus indirect costs are included together under the cap (when the cap is provided in the full solicitation).

20) What should an applicant avoid doing when positioning their project for this award?

Applicants should avoid framing the work as a predictable next step, a small extension of existing findings, or a straightforward repackaging of an established approach. The program description suggests these approaches will be viewed as poor fits compared to truly novel, high-risk/high-reward ideas.